Hanmi Pharmaceutical continued its strong performance in the outpatient prescription market. With self-developed new complex drugs such as Rosuzet and Amosartan, it has been at the forefront of domestic and foreign pharmaceutical companies. Chong Kun Dang and Daewoong Pharmaceutical took the lead with high growth, while Daewoong Bio showed a steep rise.

According to UBIST, a pharmaceutical research institute, on the 24th, Hanmi Pharm raised the highest outpatient prescription amount of 219 billion won in the first quarter, taking the lead among domestic and foreign pharmaceutical companies. It rose 7.0% from the previous year, predicting the lead for six consecutive years. Hanmi Pharmaceutical ranked first